Shinji Yamashita

Shinji Yamashita

Auto-generated profile, based on publicly available information

Shinji Yamashita

Department of Neurosurgery, Division of Clinical Neuroscience, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in OncoImmunology
Verified
Journal Article
Open access
KGKonrad Gabrusiewicz
Konrad Gabrusiewicz
XLXu Li
Xu Li
JWJun Wei
Jun Wei
YHYuuri Hashimoto
Yuuri Hashimoto
AMAnantha L. Marisetty
Anantha L. Marisetty
Amy B. HeimbergerAmy B. Heimberger
Amy B. Heimberger
Exosomes can mediate a dynamic method of communication between malignancies, including those sequestered in the central nervous system and the immune system. We sought to determine whether exosomes from glioblastoma (GBM)-derived stem cells (GSCs) can induce immunosuppression. We report that GSC-derived exosomes (GDEs) have a predilection for monocytes, the precursor to macrophages. The GDEs traverse the monocyte cytoplasm, cause a reorganization of the actin cytoskeleton, and skew monocytes toward the immune suppresive M2 phenotype, including programmed death-ligand 1 (PD-L1) expression. Mass spectrometry analysis demonstrated that the GDEs contain a variety of components, including members of the signal transducer and activator of transcription 3 (STAT3) pathway that functionally mediate this immune suppressive switch. Western blot analysis revealed that upregulation of PD-L1 in GSC exosome-treated monocytes and GBM-patient-infiltrating CD14+ cells predominantly correlates with increased phosphorylation of STAT3, and in some cases, with phosphorylated p70S6 kinase and Erk1/2. Cumulatively, these data indicate that GDEs are secreted GBM-released factors that are potent modulators of the GBM-associated immunosuppressive microenvironment.

1 March 2019 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
SYShinji Yamashita
Shinji Yamashita
KYKiyotaka Yokogami
Kiyotaka Yokogami
FMFumitaka Matsumoto
Fumitaka Matsumoto
KSKiyotaka Saito
Kiyotaka Saito
AMAsako Mizuguchi
Asako Mizuguchi
HTHideo Takeshima
Hideo Takeshima
OBJECTIVE: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a prognostic factor in adults with glioblastoma (GBM); it also yields information that is useful for clinical decision-making in elderly GBM patients. While pyrosequencing is the gold standard for the evaluation of the methylation status of MGMT, methylation-sensitive polymerase chain reaction (MS-PCR) assay continues to be used widely. Although MS-PCR results exhibited a good correlation with the prognosis of patients with GBM treated under the Stupp protocol, interpretation of the bands is based on subjective judgment, and the assay cannot be used to analyze heterogeneously methylated samples. We assessed whether methylation-sensitive high-resolution melting (MS-HRM) is an alternative to MS-PCR.METHODS: The authors prepared 3 primer sets that covered CpG 72–89 for MS-HRM analysis to determine the methylation levels of 6 human glioma cell lines. The results were validated by bisulfite sequencing of cloned alleles. The authors also subjected surgical samples from 75 GBM patients treated with temozolomide (TMZ) to MS-HRM to assess the MGMT methylation status and compared the findings with MS-PCR results using receiver operating characteristic (ROC), univariate, and multivariate analyses.RESULTS: There was a strong correlation between the methylation levels of the 6 glioma cell lines evaluated by MS-HRM and by bisulfite sequencing; with primers 1 and 2, the correlation was significant (r = 0.959 and r = 0.960, respectively, p < 0.01). Based on log-rank analysis, MS-HRM was significantly better than MS-PCR for predicting progression-free survival (PFS) and overall survival (OS) based on the methylation status of the MGMT promoter (PFS predicted by MS-HRM and MS-PCR = 0.00023 and 0.0035, respectively; OS = 0.00019 and 0.00028, respectively). ROC analysis showed that the area under the curve was larger with MS-HRM than with MS-PCR (PFS: 0.723 vs 0.635; OS: 0.716 vs 0.695). Based on multivariate Cox regression analysis, MS-HRM was significantly better than MS-PCR for predicting the treatment outcome (MS-HRM vs MS-PCR: PFS, p = 0.001 vs 0.207; OS, p = 0.013 vs 0.135).CONCLUSIONS: The authors’ findings show that MS-HRM is superior to MS-PCR for the detection of MGMT promoter methylation. They suggest MS-HRM as an alternative to MS-PCR for assessing the prognosis of patients with GBM.

28 April 2022 in Brain Tumor Pathology
Verified
Journal Article
Closed access
PDF file
SYShinji Yamashita
Shinji Yamashita
HTHideo Takeshima
Hideo Takeshima
YKYoshihito Kadota
Yoshihito Kadota
MAMinako Azuma
Minako Azuma
TFTsuyoshi Fukushima
Tsuyoshi Fukushima
KYKiyotaka Yokogami
Kiyotaka Yokogami

13 April 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SYShinji Yamashita
Shinji Yamashita
HTHideo Takeshima
Hideo Takeshima
NHNobuhiro Hata
Nobuhiro Hata
HUHiroyuki Uchida
Hiroyuki Uchida
NSNaoki Shinojima
Naoki Shinojima
KGKyushu Neuro-Oncology Study Group
Kyushu Neuro-Oncology Study Group

1 January 1999 in Drug Delivery System
Verified
Journal Article
Open access
PDF file
TSTomotaka Shingaki
Tomotaka Shingaki
TSToshiyasu Sakane
Toshiyasu Sakane
SYShinji Yamashita
Shinji Yamashita
HSHitoshi Sezaki
Hitoshi Sezaki
YTYoshiharu Tokunaga
Yoshiharu Tokunaga
SSShobu Shibata
Shobu Shibata
総合学術電子ジャーナルサイト「J-STAGE」-国内で発行された学術論文全文を読むことのできる、日本最大級の総合電子ジャーナルプラットフォームです。

2 September 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
KMKAZUYA MOTOMURA
KAZUYA MOTOMURA
KSKeita Sasaki
Keita Sasaki
NSNarushi Sugii
Narushi Sugii
SYShigeru Yamaguchi
Shigeru Yamaguchi
HIHirotaka Inoue
Hirotaka Inoue
T(the Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
the Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)
Background: This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved. Methods: We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL. Results: The most used regimen (46.8%) for GBM in patients aged ≤74 years was ‘Surgery + radiotherapy concomitant with temozolomide’. This regimen’s total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, ‘Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy’ was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month). Conclusions: Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors.